University of Colorado

University of Alberta

Pence, Inc.

Other

Mcgill University

S.p.i. Synthetic Peptides Incorporated

Robert S Hodges

Randall Thomas Irvin

Lajos Gera

R Bruce Lennox

William Paranchych

Kok K Lee

Ziqing Jiang

Sastry A Parimi

Leslie H Kondejewski

Colin T Mant

Peter C Doig

Robert E W Hancock

Wah Yau Wong

Pamela A Sokol

Erin Van Schaik

Yuxin Chen

Hasmukh B Sheth

Margaret C Neville

Neal Beeman

Carmen Giltner

Donald E Woods

Glen D Armstrong

David R Bundle

Daniel C Chan

Arne Holm

Pavel Kitov

David Scott Wishart

Peter Hegyes

Michael Vasil

Dick E Zoutman

Michael E Houston, Jr

Devon L Husband

Craig Railton

Lei Yu

Susan W Farmer

Paul J Cachia

Ronald N McElhaney

Ruthven N A H Lewis

Elmar J Prenner

Paul A Bunn

Antimicrobial agents, including antimicrobial peptides (AMPs), and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptide variants that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganismsand, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPs change selectivity from broad spectrum antimicrobial activity to Gram-negative selectivity.

Antimicrobial peptides and methods of treating gram-negative pathogens: polar and non-polar face analogs

Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganismsand, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.

Dermaseptin-type and piscidin-type antimicrobial peptides

Silylalkyloxyaryl compounds useful as anti-cancer agents. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of melanoma, colon, neuroblastoma, bladder, breast, lung, pancreatic, melanoma, sarcoma, lymphoma or gastric cancer.

Silylalkyloxyaryl compounds and methods for treating cancer

Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especiallyand. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, including as broad spectrum antibiotics.

Antimicrobial peptides

Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, specificity, resistance to degradation desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides result from structure-based rational design relating to antimicrobial peptide V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Some peptides contain one or more (or all) amino acids in the D configuration. Compositions disclosed herein have useful clinical potential as antibiotics including broad spectrum antibiotics.

Antimicrobial peptides and methods of use

The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin.

Tight junction protein modulators and uses thereof

Flurbiprofen analog compounds having an amino acid derivatized at the flurbiprofen alkanoic acid carboxyl group and terminating at an ester or amide group are effective in inhibiting cancer cells in vitro and inhibiting the growth of cancers in viva. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of lung, pancreatic and head and neck cancers.

Flurbiprofen analogs and methods of use in treating cancer

The present invention relates to a composition, device and method for preventing or inhibiting biofilm formation on biotic or abiotic surfaces. The composition comprises a peptide based on the C-terminal receptor binding domain oftype IV pilin, which binds to an abiotic surface (e.g., steel, plastic) with high affinity and prevents binding of a variety ofstrains to the surface. The inventive composition represents a non-toxic inhibitor for biofilm formation, particularly on an abiotic surface, which is responsible for a large number of problematic diseases and massive economic losses. The inventive method is useful as a safe and environmentally friendly means of modifying a surface of a variety of biomedical, nanotechnological, and biotechnological devices or articles.

Non-toxic biofilm inhibitor

Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein have useful clinical potential as antibiotics including broad spectrum antibiotics.

The present invention relates to a composition and method for preventing or inhibiting biofilm formation on biotic or abiotic surfaces. The composition comprises a peptide based on the C-terminal receptor binding domain oftype IV pilin, which binds to an abiotic surface (e.g., steel, plastic) with high affinity and prevents binding of a variety ofstrains to the surface. The inventive composition represents a non-toxic inhibitor for biofilm formation, particularly on an abiotic surface, which is responsible for a large number of problematic diseases and massive economic losses. The inventive method is useful as a safe and environmentally friendly means of modifying a surface of a variety of biomedical, nanotechnological, and biotechnological devices or articles.

The invention relates to the use of constrained coiled-coil polypeptides to mimic &#x3b1;-helical structural elements of native proteins. These constrained peptidyl mimetics are used to generate and/or identify ligands which selectively bind the &#x3b1;-helical segment contained in the native protein.

Polypeptide compositions formed using a coiled-coil template and methods of use

The invention relates to the use of constrained coiled-coil polypeptides to mimic &#x3b1;-helical structural elements of native proteins. These constrained peptidyl mimetics are used to generate and/or identify ligands, which selectively bind the &#x3b1;-helical segment contained in the native protein.

A C-terminal pilin peptide vaccine for immunizing or treating a patient for infection by a (PA) infection is disclosed. The peptide comprises the peptide identified as SEQ ID NOS. 3-6; and a carrier protein conjugated to the peptide. Also disclosed is a pilin peptide C-terminal PA pilin peptide having the amino acid sequence identified as SEQ ID NO:3, and analogs thereof having one of residues T, K, or A at position 130, D, T, or N at position 132, Q, A, or V at position 133, E, P, N, or A at position 135, Q, M, or K at position 136, and I, T, L, or R at position 138, excluding SEQ ID NOS: 1, 2, 9, 10, and 11, and the ability to cross-react with antibodies against the corresponding C-terminal peptides from PA strains PAK and PAO.

Vaccine for Pseudomonas aeruginosa

Growing community of inventors

Denver, CO, United States of America

Robert S Hodges